CRISPR

R&D

The innovative future of CRISPR tech

CRISPR-based therapies have moved from theory to reality, after the recent landmark approval of the first such treatment by the FDA.

R&D

JP Morgan 2024 – Jonah Comstock talks with Trevor Martin

JP Morgan 2024 – Trevor Martin

Editor-in-chief Jonah Comstock caught up with Trevor Martin, co-founder and CEO of Mammoth Biosciences

News

Intellia’s president and chief executive John Leonard

Intellia’s CRISPR drug could offer one-shot HAE treatment

A single dose of a gene-editing drug being developed by Intellia Therapeutics almost eliminated attacks in patients with hereditary angioedema (HAE) in a clinical trial, p

News

A giemsa stained blood smear from a person with beta thalassaemia

First CRISPR drug Casgevy gets swift second approval

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-

Market Access

Nine for 2024, Pt 1: From fragility to resilience

This year was a year of significant new beginnings for pharma and healthcare, yet, it was still impacted by the long-term fallouts of the pandemic.

R&D

Partner Content

CRISPR-Based Therapy Analytical Development Summit

CRISPR-based therapies are undergoing a remarkable evolution, with drug developers striving to enhance the safety, precision and efficacy of their products.